Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI

Onco-Innovations Limited

By The Northwire Desk — AI Analysis May 12, 2026 · 18:00 ONCO · 1.06 ONCO-INNOVATIONS LIMITED
Executive Summary
  • Date: 2026-05-12
  • Headline: Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
  • Partner: AstraZeneca via subsidiary Inka Health Corp.
  • Program: PROmAI (Predicting Oncology Outcomes using Multimodal Artificial Intelligence)
  • Focus: Development of AI-based approaches to improve prediction of clinical outcomes using multimodal datasets (molecular, clinical, imaging).
  • Objective: Strengthen decision support tools for translational research and clinical development strategy.
  • Context: Follows previous AI collaborations with OneMedNet (April 2026) and Kuano (November 2025).
Material Impact
  • Strategic Validation: The partnership with AstraZeneca validates the company's AI-driven oncology thesis, moving beyond smaller partners like OneMedNet or Kuano.
  • Financial Impact: No immediate revenue or capital infusion is disclosed in this release; it is a research collaboration.
  • Market Context: The stock has declined over 98% from its May 2025 highs ($39.53) to current levels ($0.41). Recent private placements occurred at $0.65 (March 2026), meaning the current price is significantly below recent institutional entry points.
  • Catalyst Status: While positive, this news aligns with a pattern of AI partnerships announced throughout 2025 and early 2026. It does not represent a sudden strategic pivot or M&A event that would qualify as "Game Changer."
  • Risk Mitigation: The collaboration helps de-risk the AI component but does not address the immediate clinical risk of the PNKP Inhibitor (ONC010) or the company's cash burn rate.
ONCO · Price
Company Overview
  • Company: Onco-Innovations Limited.
  • Flagship Project: PNKP Inhibitor Technology (Drug Candidate ONC010).
  • Mechanism: DNA Damage Response Inhibitor encapsulated in a proprietary nanoparticle micelle for tumor-targeted delivery.
  • AI Component: PROmAI program and SynoGraph AI model for evidence generation and patient identification.
  • Development Stage: Preclinical transitioning to IND-enabling studies (Phase 1 readiness).
  • Key Partners: Dalton Pharma Services (Manufacturing), Nucro-Technics (Bioanalysis), AstraZeneca, OneMedNet, Kuano.
Read the original news release →

More from ONCO-INNOVATIONS LIMITED

Jun 30, 2026 · 19:00

Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

Financings Jun 30, 2026 · 18:00

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

M&A / Property Jun 26, 2026 · 18:00

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Other Jun 26, 2026 · 08:30

Canadian preclinical-stage oncology company developing PNKP inhibitor ONC010 and AI-driven SynoGraph platform.

Other Jun 25, 2026 · 08:30

Preclinical PNKP inhibitor developer burns cash and raises capital while marketing AI oncology partnerships to a niche market.

Other Jun 23, 2026 · 18:00

Preclinical Oncology Developer Secures Polymer Partner to De-Risk ONC010 Manufacturing Ahead of IND Filing

M&A / Property